**Virginia Mason**

**Evolving Care Across the Cancer Spectrum: The Latest Update in Colorectal Cancer**

March 21, 2025 7:30 AM

Volney Richmond Auditorium

**Description**

Virginia Mason Franciscan Health is a recognized leader across the spectrum of colorectal cancer care. This symposium aims to present important considerations in individualizing care across the cancer care continuum, with a focus on the increasing incidence of young-onset colorectal cancer. Topics include unique risk factors in the role of the microbiome and genetics in colorectal cancer development, fertility considerations and the latest in screening options.  
  
Our midday session will focus on important contemporary debates in colorectal cancer, and an application in a multidisciplinary tumor board context. Lastly, we will focus on managing treatment-related comorbidities and the nuances of continued surveillance.

The overall objective of the course is to demonstrate the benefits of contemporary, personalized care — nuanced decision making, latest trials, and individualized care as offered at a Center of Excellence.  
  
Teaching methods include lecture, Q&A with faculty, case presentation and case discussion.

**Learning Objectives**

1 Discuss epidemiologic trends related to young age of onset colorectal cancer

2 Describe how specific intratumoral bacteria are associated with immune changes in the tumor microenvironment

3 Explore the emerging hereditary and environmental explanations in early onset colon cancers

4 Outline fertility preservation options available for colorectal cancer patients

5 Review consensus guidelines for anal cancer screening: who, how, when and why

6 Summarize guidelines suggesting TME-first approach in stage 1 rectal cancer

7 Explain the treatment and follow-up protocols for organ preservation

8 Discuss latest data on neoadjuvant chemotherapy for colon cancer

9 Identify scenarios in which up front surgery avoids over treatment with chemotherapy

10 Develop a framework for patient centered decision making in RT management decisions

11 Describe scenarios in which radiation can be avoided in locally advanced rectal cancer

12 Formulate anticoagulation plans based on current evidence, balancing risks, benefits, and patient preferences

13 Review endoscopic surveillance for colon cancer screening

14 Explain how MRI is the optimal modality for evaluation of extramural venous invasion (EMVI)

15 Assess the risk, diagnosis, and management of hepatotoxicity of chemotherapy and immunotherapy for CRC

**Accreditation**

Virginia Mason is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Logo, company name

Description automatically generated

**Credit Designation**

Virginia Mason designates this activity for a maximum of 5.25 *AMA PRA Category 1 Credit(s)*™.

**Faculty & Planners**

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| David M. Aboulafia, MD | Faculty | Nothing to disclose - 01/13/2025 |
| Sarah A. Ackermann, CCRC | Planning Committee Member | Nothing to disclose - 12/19/2024 |
| Bruce S. Lin, MD | Course Co-Director, Faculty | Grant or research support-Merck and Company, Inc.|Grant or research support-Tvardi|Grant or research support-Genentech, Inc.|Grant or research support-Exelixis|Grant or research support-Cardiff Oncology|Grant or research support-Zymeworks|Grant or research support-GlaxoSmithKline|Grant or research support-Relay Therapeutics|Grant or research support-Incyte - 12/20/2024 |
| Blaire E. Burman, MD | Faculty | Nothing to disclose - 03/10/2025 |
| Vlad Simianu, MD, MPH | Course Co-Director, Faculty | Consulting Fee-C-SATS (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-BD|Other: Travel and Education Support-Intuitive Surgical (Relationship has ended) - 05/18/2024 |
| Jenny Kaplan, MD | Faculty | Nothing to disclose - 01/24/2025 |
| Amber B. Post, MD, PhD | Course Co-Director, Faculty | Nothing to disclose - 03/20/2025 |
| Gautam Mankaney, MD | Faculty | Nothing to disclose - 09/19/2024 |
| Sirisha Jain, MD | Faculty | Nothing to disclose - 02/24/2025 |
| Emily Stevens, MD, PhD | Faculty | Nothing to disclose - 03/17/2025 |
| Ravi Moonka, MD, ASCRS | Faculty | Nothing to disclose - 03/17/2025 |
| Amanda Loh, MD | Faculty | Nothing to disclose - 03/17/2025 |
| Allyson Byrd, PhD | Faculty | Employment-Genentech, Inc. (Relationship has ended) - 03/14/2025 |
| Mohammad Hissourou III, MD | Faculty | Nothing to disclose - 03/17/2025 |
| Marianne E. Dubard-Gault, MD, MS | Faculty | Nothing to disclose - 03/14/2025 |
| Yi-Qian Nancy You, MD, MHSc, FACS | Faculty | Nothing to disclose - 02/13/2025 |
| Shelun Tsai, MD | Faculty | Nothing to disclose - 02/21/2025 |
| Rajeev Misra, DO, MS, FACS | Faculty | Honoraria-Intuitive Surgical - 03/11/2025 |

**Commercial Support**

This activity has been developed without commercial support.

**Virginia Mason**

**Evolving Care Across the Cancer Spectrum: The Latest Update in Colorectal Cancer**

March 21, 2025 7:30 AM

Volney Richmond Auditorium

**Description**

Virginia Mason Franciscan Health is a recognized leader across the spectrum of colorectal cancer care. This symposium aims to present important considerations in individualizing care across the cancer care continuum, with a focus on the increasing incidence of young-onset colorectal cancer. Topics include unique risk factors in the role of the microbiome and genetics in colorectal cancer development, fertility considerations and the latest in screening options.  
  
Our midday session will focus on important contemporary debates in colorectal cancer, and an application in a multidisciplinary tumor board context. Lastly, we will focus on managing treatment-related comorbidities and the nuances of continued surveillance.

The overall objective of the course is to demonstrate the benefits of contemporary, personalized care — nuanced decision making, latest trials, and individualized care as offered at a Center of Excellence.  
  
Teaching methods include lecture, Q&A with faculty, case presentation and case discussion.

**Learning Objectives**

1 Discuss epidemiologic trends related to young age of onset colorectal cancer

2 Describe how specific intratumoral bacteria are associated with immune changes in the tumor microenvironment

3 Explore the emerging hereditary and environmental explanations in early onset colon cancers

4 Outline fertility preservation options available for colorectal cancer patients

5 Review consensus guidelines for anal cancer screening: who, how, when and why

6 Summarize guidelines suggesting TME-first approach in stage 1 rectal cancer

7 Explain the treatment and follow-up protocols for organ preservation

8 Discuss latest data on neoadjuvant chemotherapy for colon cancer

9 Identify scenarios in which up front surgery avoids over treatment with chemotherapy

10 Develop a framework for patient centered decision making in RT management decisions

11 Describe scenarios in which radiation can be avoided in locally advanced rectal cancer

12 Formulate anticoagulation plans based on current evidence, balancing risks, benefits, and patient preferences

13 Review endoscopic surveillance for colon cancer screening

14 Explain how MRI is the optimal modality for evaluation of extramural venous invasion (EMVI)

15 Assess the risk, diagnosis, and management of hepatotoxicity of chemotherapy and immunotherapy for CRC

**Accreditation**

Virginia Mason is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Logo, company name

Description automatically generated

**Credit Designation**

Virginia Mason designates this activity for a maximum of 5.25 *AMA PRA Category 1 Credit(s)*™.

**Faculty & Planners**

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| David M. Aboulafia, MD | Faculty | Nothing to disclose - 01/13/2025 |
| Sarah A. Ackermann, CCRC | Planning Committee Member | Nothing to disclose - 12/19/2024 |
| Bruce S. Lin, MD | Course Co-Director, Faculty | Grant or research support-Merck and Company, Inc.|Grant or research support-Tvardi|Grant or research support-Genentech, Inc.|Grant or research support-Exelixis|Grant or research support-Cardiff Oncology|Grant or research support-Zymeworks|Grant or research support-GlaxoSmithKline|Grant or research support-Relay Therapeutics|Grant or research support-Incyte - 12/20/2024 |
| Blaire E. Burman, MD | Faculty | Nothing to disclose - 03/10/2025 |
| Vlad Simianu, MD, MPH | Course Co-Director, Faculty | Consulting Fee-C-SATS (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-BD|Other: Travel and Education Support-Intuitive Surgical (Relationship has ended) - 05/18/2024 |
| Jenny Kaplan, MD | Faculty | Nothing to disclose - 01/24/2025 |
| Amber B. Post, MD, PhD | Course Co-Director, Faculty | Nothing to disclose - 03/20/2025 |
| Gautam Mankaney, MD | Faculty | Nothing to disclose - 09/19/2024 |
| Sirisha Jain, MD | Faculty | Nothing to disclose - 02/24/2025 |
| Emily Stevens, MD, PhD | Faculty | Nothing to disclose - 03/17/2025 |
| Ravi Moonka, MD, ASCRS | Faculty | Nothing to disclose - 03/17/2025 |
| Amanda Loh, MD | Faculty | Nothing to disclose - 03/17/2025 |
| Allyson Byrd, PhD | Faculty | Employment-Genentech, Inc. (Relationship has ended) - 03/14/2025 |
| Mohammad Hissourou III, MD | Faculty | Nothing to disclose - 03/17/2025 |
| Marianne E. Dubard-Gault, MD, MS | Faculty | Nothing to disclose - 03/14/2025 |
| Yi-Qian Nancy You, MD, MHSc, FACS | Faculty | Nothing to disclose - 02/13/2025 |
| Shelun Tsai, MD | Faculty | Nothing to disclose - 02/21/2025 |
| Rajeev Misra, DO, MS, FACS | Faculty | Honoraria-Intuitive Surgical - 03/11/2025 |

**Commercial Support**

This activity has been developed without commercial support.

**Virginia Mason**

**Evolving Care Across the Cancer Spectrum: The Latest Update in Colorectal Cancer**

March 21, 2025 7:30 AM

Volney Richmond Auditorium

**Description**

Virginia Mason Franciscan Health is a recognized leader across the spectrum of colorectal cancer care. This symposium aims to present important considerations in individualizing care across the cancer care continuum, with a focus on the increasing incidence of young-onset colorectal cancer. Topics include unique risk factors in the role of the microbiome and genetics in colorectal cancer development, fertility considerations and the latest in screening options.  
  
Our midday session will focus on important contemporary debates in colorectal cancer, and an application in a multidisciplinary tumor board context. Lastly, we will focus on managing treatment-related comorbidities and the nuances of continued surveillance.

The overall objective of the course is to demonstrate the benefits of contemporary, personalized care — nuanced decision making, latest trials, and individualized care as offered at a Center of Excellence.  
  
Teaching methods include lecture, Q&A with faculty, case presentation and case discussion.

**Learning Objectives**

1 Discuss epidemiologic trends related to young age of onset colorectal cancer

2 Describe how specific intratumoral bacteria are associated with immune changes in the tumor microenvironment

3 Explore the emerging hereditary and environmental explanations in early onset colon cancers

4 Outline fertility preservation options available for colorectal cancer patients

5 Review consensus guidelines for anal cancer screening: who, how, when and why

6 Summarize guidelines suggesting TME-first approach in stage 1 rectal cancer

7 Explain the treatment and follow-up protocols for organ preservation

8 Discuss latest data on neoadjuvant chemotherapy for colon cancer

9 Identify scenarios in which up front surgery avoids over treatment with chemotherapy

10 Develop a framework for patient centered decision making in RT management decisions

11 Describe scenarios in which radiation can be avoided in locally advanced rectal cancer

12 Formulate anticoagulation plans based on current evidence, balancing risks, benefits, and patient preferences

13 Review endoscopic surveillance for colon cancer screening

14 Explain how MRI is the optimal modality for evaluation of extramural venous invasion (EMVI)

15 Assess the risk, diagnosis, and management of hepatotoxicity of chemotherapy and immunotherapy for CRC

**Accreditation**

Virginia Mason is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Logo, company name

Description automatically generated

**Credit Designation**

Virginia Mason designates this activity for a maximum of 5.25 *AMA PRA Category 1 Credit(s)*™.

**Faculty & Planners**

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| David M. Aboulafia, MD | Faculty | Nothing to disclose - 01/13/2025 |
| Sarah A. Ackermann, CCRC | Planning Committee Member | Nothing to disclose - 12/19/2024 |
| Bruce S. Lin, MD | Course Co-Director, Faculty | Grant or research support-Merck and Company, Inc.|Grant or research support-Tvardi|Grant or research support-Genentech, Inc.|Grant or research support-Exelixis|Grant or research support-Cardiff Oncology|Grant or research support-Zymeworks|Grant or research support-GlaxoSmithKline|Grant or research support-Relay Therapeutics|Grant or research support-Incyte - 12/20/2024 |
| Blaire E. Burman, MD | Faculty | Nothing to disclose - 03/10/2025 |
| Vlad Simianu, MD, MPH | Course Co-Director, Faculty | Consulting Fee-C-SATS (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-BD|Other: Travel and Education Support-Intuitive Surgical (Relationship has ended) - 05/18/2024 |
| Jenny Kaplan, MD | Faculty | Nothing to disclose - 01/24/2025 |
| Amber B. Post, MD, PhD | Course Co-Director, Faculty | Nothing to disclose - 03/20/2025 |
| Gautam Mankaney, MD | Faculty | Nothing to disclose - 09/19/2024 |
| Sirisha Jain, MD | Faculty | Nothing to disclose - 02/24/2025 |
| Emily Stevens, MD, PhD | Faculty | Nothing to disclose - 03/17/2025 |
| Ravi Moonka, MD, ASCRS | Faculty | Nothing to disclose - 03/17/2025 |
| Amanda Loh, MD | Faculty | Nothing to disclose - 03/17/2025 |
| Allyson Byrd, PhD | Faculty | Employment-Genentech, Inc. (Relationship has ended) - 03/14/2025 |
| Mohammad Hissourou III, MD | Faculty | Nothing to disclose - 03/17/2025 |
| Marianne E. Dubard-Gault, MD, MS | Faculty | Nothing to disclose - 03/14/2025 |
| Yi-Qian Nancy You, MD, MHSc, FACS | Faculty | Nothing to disclose - 02/13/2025 |
| Shelun Tsai, MD | Faculty | Nothing to disclose - 02/21/2025 |
| Rajeev Misra, DO, MS, FACS | Faculty | Honoraria-Intuitive Surgical - 03/11/2025 |

**Commercial Support**

This activity has been developed without commercial support.

**Virginia Mason**

**Evolving Care Across the Cancer Spectrum: The Latest Update in Colorectal Cancer**

March 21, 2025 7:30 AM

Volney Richmond Auditorium

**Description**

Virginia Mason Franciscan Health is a recognized leader across the spectrum of colorectal cancer care. This symposium aims to present important considerations in individualizing care across the cancer care continuum, with a focus on the increasing incidence of young-onset colorectal cancer. Topics include unique risk factors in the role of the microbiome and genetics in colorectal cancer development, fertility considerations and the latest in screening options.  
  
Our midday session will focus on important contemporary debates in colorectal cancer, and an application in a multidisciplinary tumor board context. Lastly, we will focus on managing treatment-related comorbidities and the nuances of continued surveillance.

The overall objective of the course is to demonstrate the benefits of contemporary, personalized care — nuanced decision making, latest trials, and individualized care as offered at a Center of Excellence.  
  
Teaching methods include lecture, Q&A with faculty, case presentation and case discussion.

**Learning Objectives**

1 Discuss epidemiologic trends related to young age of onset colorectal cancer

2 Describe how specific intratumoral bacteria are associated with immune changes in the tumor microenvironment

3 Explore the emerging hereditary and environmental explanations in early onset colon cancers

4 Outline fertility preservation options available for colorectal cancer patients

5 Review consensus guidelines for anal cancer screening: who, how, when and why

6 Summarize guidelines suggesting TME-first approach in stage 1 rectal cancer

7 Explain the treatment and follow-up protocols for organ preservation

8 Discuss latest data on neoadjuvant chemotherapy for colon cancer

9 Identify scenarios in which up front surgery avoids over treatment with chemotherapy

10 Develop a framework for patient centered decision making in RT management decisions

11 Describe scenarios in which radiation can be avoided in locally advanced rectal cancer

12 Formulate anticoagulation plans based on current evidence, balancing risks, benefits, and patient preferences

13 Review endoscopic surveillance for colon cancer screening

14 Explain how MRI is the optimal modality for evaluation of extramural venous invasion (EMVI)

15 Assess the risk, diagnosis, and management of hepatotoxicity of chemotherapy and immunotherapy for CRC

**Accreditation**

Virginia Mason is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Logo, company name

Description automatically generated

**Credit Designation**

Virginia Mason designates this activity for a maximum of 5.25 *AMA PRA Category 1 Credit(s)*™.

**Faculty & Planners**

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| David M. Aboulafia, MD | Faculty | Nothing to disclose - 01/13/2025 |
| Sarah A. Ackermann, CCRC | Planning Committee Member | Nothing to disclose - 12/19/2024 |
| Bruce S. Lin, MD | Course Co-Director, Faculty | Grant or research support-Merck and Company, Inc.|Grant or research support-Tvardi|Grant or research support-Genentech, Inc.|Grant or research support-Exelixis|Grant or research support-Cardiff Oncology|Grant or research support-Zymeworks|Grant or research support-GlaxoSmithKline|Grant or research support-Relay Therapeutics|Grant or research support-Incyte - 12/20/2024 |
| Blaire E. Burman, MD | Faculty | Nothing to disclose - 03/10/2025 |
| Vlad Simianu, MD, MPH | Course Co-Director, Faculty | Consulting Fee-C-SATS (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-BD|Other: Travel and Education Support-Intuitive Surgical (Relationship has ended) - 05/18/2024 |
| Jenny Kaplan, MD | Faculty | Nothing to disclose - 01/24/2025 |
| Amber B. Post, MD, PhD | Course Co-Director, Faculty | Nothing to disclose - 03/20/2025 |
| Gautam Mankaney, MD | Faculty | Nothing to disclose - 09/19/2024 |
| Sirisha Jain, MD | Faculty | Nothing to disclose - 02/24/2025 |
| Emily Stevens, MD, PhD | Faculty | Nothing to disclose - 03/17/2025 |
| Ravi Moonka, MD, ASCRS | Faculty | Nothing to disclose - 03/17/2025 |
| Amanda Loh, MD | Faculty | Nothing to disclose - 03/17/2025 |
| Allyson Byrd, PhD | Faculty | Employment-Genentech, Inc. (Relationship has ended) - 03/14/2025 |
| Mohammad Hissourou III, MD | Faculty | Nothing to disclose - 03/17/2025 |
| Marianne E. Dubard-Gault, MD, MS | Faculty | Nothing to disclose - 03/14/2025 |
| Yi-Qian Nancy You, MD, MHSc, FACS | Faculty | Nothing to disclose - 02/13/2025 |
| Shelun Tsai, MD | Faculty | Nothing to disclose - 02/21/2025 |
| Rajeev Misra, DO, MS, FACS | Faculty | Honoraria-Intuitive Surgical - 03/11/2025 |

**Commercial Support**

This activity has been developed without commercial support.

**Virginia Mason**

**Evolving Care Across the Cancer Spectrum: The Latest Update in Colorectal Cancer**

March 21, 2025 7:30 AM

Volney Richmond Auditorium

**Description**

Virginia Mason Franciscan Health is a recognized leader across the spectrum of colorectal cancer care. This symposium aims to present important considerations in individualizing care across the cancer care continuum, with a focus on the increasing incidence of young-onset colorectal cancer. Topics include unique risk factors in the role of the microbiome and genetics in colorectal cancer development, fertility considerations and the latest in screening options.  
  
Our midday session will focus on important contemporary debates in colorectal cancer, and an application in a multidisciplinary tumor board context. Lastly, we will focus on managing treatment-related comorbidities and the nuances of continued surveillance.

The overall objective of the course is to demonstrate the benefits of contemporary, personalized care — nuanced decision making, latest trials, and individualized care as offered at a Center of Excellence.  
  
Teaching methods include lecture, Q&A with faculty, case presentation and case discussion.

**Learning Objectives**

1 Discuss epidemiologic trends related to young age of onset colorectal cancer

2 Describe how specific intratumoral bacteria are associated with immune changes in the tumor microenvironment

3 Explore the emerging hereditary and environmental explanations in early onset colon cancers

4 Outline fertility preservation options available for colorectal cancer patients

5 Review consensus guidelines for anal cancer screening: who, how, when and why

6 Summarize guidelines suggesting TME-first approach in stage 1 rectal cancer

7 Explain the treatment and follow-up protocols for organ preservation

8 Discuss latest data on neoadjuvant chemotherapy for colon cancer

9 Identify scenarios in which up front surgery avoids over treatment with chemotherapy

10 Develop a framework for patient centered decision making in RT management decisions

11 Describe scenarios in which radiation can be avoided in locally advanced rectal cancer

12 Formulate anticoagulation plans based on current evidence, balancing risks, benefits, and patient preferences

13 Review endoscopic surveillance for colon cancer screening

14 Explain how MRI is the optimal modality for evaluation of extramural venous invasion (EMVI)

15 Assess the risk, diagnosis, and management of hepatotoxicity of chemotherapy and immunotherapy for CRC

**Accreditation**

Virginia Mason is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Logo, company name

Description automatically generated

**Credit Designation**

Virginia Mason designates this activity for a maximum of 5.25 *AMA PRA Category 1 Credit(s)*™.

**Faculty & Planners**

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| David M. Aboulafia, MD | Faculty | Nothing to disclose - 01/13/2025 |
| Sarah A. Ackermann, CCRC | Planning Committee Member | Nothing to disclose - 12/19/2024 |
| Bruce S. Lin, MD | Course Co-Director, Faculty | Grant or research support-Merck and Company, Inc.|Grant or research support-Tvardi|Grant or research support-Genentech, Inc.|Grant or research support-Exelixis|Grant or research support-Cardiff Oncology|Grant or research support-Zymeworks|Grant or research support-GlaxoSmithKline|Grant or research support-Relay Therapeutics|Grant or research support-Incyte - 12/20/2024 |
| Blaire E. Burman, MD | Faculty | Nothing to disclose - 03/10/2025 |
| Vlad Simianu, MD, MPH | Course Co-Director, Faculty | Consulting Fee-C-SATS (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-BD|Other: Travel and Education Support-Intuitive Surgical (Relationship has ended) - 05/18/2024 |
| Jenny Kaplan, MD | Faculty | Nothing to disclose - 01/24/2025 |
| Amber B. Post, MD, PhD | Course Co-Director, Faculty | Nothing to disclose - 03/20/2025 |
| Gautam Mankaney, MD | Faculty | Nothing to disclose - 09/19/2024 |
| Sirisha Jain, MD | Faculty | Nothing to disclose - 02/24/2025 |
| Emily Stevens, MD, PhD | Faculty | Nothing to disclose - 03/17/2025 |
| Ravi Moonka, MD, ASCRS | Faculty | Nothing to disclose - 03/17/2025 |
| Amanda Loh, MD | Faculty | Nothing to disclose - 03/17/2025 |
| Allyson Byrd, PhD | Faculty | Employment-Genentech, Inc. (Relationship has ended) - 03/14/2025 |
| Mohammad Hissourou III, MD | Faculty | Nothing to disclose - 03/17/2025 |
| Marianne E. Dubard-Gault, MD, MS | Faculty | Nothing to disclose - 03/14/2025 |
| Yi-Qian Nancy You, MD, MHSc, FACS | Faculty | Nothing to disclose - 02/13/2025 |
| Shelun Tsai, MD | Faculty | Nothing to disclose - 02/21/2025 |
| Rajeev Misra, DO, MS, FACS | Faculty | Honoraria-Intuitive Surgical - 03/11/2025 |

**Commercial Support**

This activity has been developed without commercial support.

**Virginia Mason**

**Evolving Care Across the Cancer Spectrum: The Latest Update in Colorectal Cancer**

March 21, 2025 7:30 AM

Volney Richmond Auditorium

**Description**

Virginia Mason Franciscan Health is a recognized leader across the spectrum of colorectal cancer care. This symposium aims to present important considerations in individualizing care across the cancer care continuum, with a focus on the increasing incidence of young-onset colorectal cancer. Topics include unique risk factors in the role of the microbiome and genetics in colorectal cancer development, fertility considerations and the latest in screening options.  
  
Our midday session will focus on important contemporary debates in colorectal cancer, and an application in a multidisciplinary tumor board context. Lastly, we will focus on managing treatment-related comorbidities and the nuances of continued surveillance.

The overall objective of the course is to demonstrate the benefits of contemporary, personalized care — nuanced decision making, latest trials, and individualized care as offered at a Center of Excellence.  
  
Teaching methods include lecture, Q&A with faculty, case presentation and case discussion.

**Learning Objectives**

1 Discuss epidemiologic trends related to young age of onset colorectal cancer

2 Describe how specific intratumoral bacteria are associated with immune changes in the tumor microenvironment

3 Explore the emerging hereditary and environmental explanations in early onset colon cancers

4 Outline fertility preservation options available for colorectal cancer patients

5 Review consensus guidelines for anal cancer screening: who, how, when and why

6 Summarize guidelines suggesting TME-first approach in stage 1 rectal cancer

7 Explain the treatment and follow-up protocols for organ preservation

8 Discuss latest data on neoadjuvant chemotherapy for colon cancer

9 Identify scenarios in which up front surgery avoids over treatment with chemotherapy

10 Develop a framework for patient centered decision making in RT management decisions

11 Describe scenarios in which radiation can be avoided in locally advanced rectal cancer

12 Formulate anticoagulation plans based on current evidence, balancing risks, benefits, and patient preferences

13 Review endoscopic surveillance for colon cancer screening

14 Explain how MRI is the optimal modality for evaluation of extramural venous invasion (EMVI)

15 Assess the risk, diagnosis, and management of hepatotoxicity of chemotherapy and immunotherapy for CRC

**Accreditation**

Virginia Mason is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Logo, company name

Description automatically generated

**Credit Designation**

Virginia Mason designates this activity for a maximum of 5.25 *AMA PRA Category 1 Credit(s)*™.

**Faculty & Planners**

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| David M. Aboulafia, MD | Faculty | Nothing to disclose - 01/13/2025 |
| Sarah A. Ackermann, CCRC | Planning Committee Member | Nothing to disclose - 12/19/2024 |
| Bruce S. Lin, MD | Course Co-Director, Faculty | Grant or research support-Merck and Company, Inc.|Grant or research support-Tvardi|Grant or research support-Genentech, Inc.|Grant or research support-Exelixis|Grant or research support-Cardiff Oncology|Grant or research support-Zymeworks|Grant or research support-GlaxoSmithKline|Grant or research support-Relay Therapeutics|Grant or research support-Incyte - 12/20/2024 |
| Blaire E. Burman, MD | Faculty | Nothing to disclose - 03/10/2025 |
| Vlad Simianu, MD, MPH | Course Co-Director, Faculty | Consulting Fee-C-SATS (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-BD|Other: Travel and Education Support-Intuitive Surgical (Relationship has ended) - 05/18/2024 |
| Jenny Kaplan, MD | Faculty | Nothing to disclose - 01/24/2025 |
| Amber B. Post, MD, PhD | Course Co-Director, Faculty | Nothing to disclose - 03/20/2025 |
| Gautam Mankaney, MD | Faculty | Nothing to disclose - 09/19/2024 |
| Sirisha Jain, MD | Faculty | Nothing to disclose - 02/24/2025 |
| Emily Stevens, MD, PhD | Faculty | Nothing to disclose - 03/17/2025 |
| Ravi Moonka, MD, ASCRS | Faculty | Nothing to disclose - 03/17/2025 |
| Amanda Loh, MD | Faculty | Nothing to disclose - 03/17/2025 |
| Allyson Byrd, PhD | Faculty | Employment-Genentech, Inc. (Relationship has ended) - 03/14/2025 |
| Mohammad Hissourou III, MD | Faculty | Nothing to disclose - 03/17/2025 |
| Marianne E. Dubard-Gault, MD, MS | Faculty | Nothing to disclose - 03/14/2025 |
| Yi-Qian Nancy You, MD, MHSc, FACS | Faculty | Nothing to disclose - 02/13/2025 |
| Shelun Tsai, MD | Faculty | Nothing to disclose - 02/21/2025 |
| Rajeev Misra, DO, MS, FACS | Faculty | Honoraria-Intuitive Surgical - 03/11/2025 |

**Commercial Support**

This activity has been developed without commercial support.

**Virginia Mason**

**Evolving Care Across the Cancer Spectrum: The Latest Update in Colorectal Cancer**

March 21, 2025 7:30 AM

Volney Richmond Auditorium

**Description**

Virginia Mason Franciscan Health is a recognized leader across the spectrum of colorectal cancer care. This symposium aims to present important considerations in individualizing care across the cancer care continuum, with a focus on the increasing incidence of young-onset colorectal cancer. Topics include unique risk factors in the role of the microbiome and genetics in colorectal cancer development, fertility considerations and the latest in screening options.  
  
Our midday session will focus on important contemporary debates in colorectal cancer, and an application in a multidisciplinary tumor board context. Lastly, we will focus on managing treatment-related comorbidities and the nuances of continued surveillance.

The overall objective of the course is to demonstrate the benefits of contemporary, personalized care — nuanced decision making, latest trials, and individualized care as offered at a Center of Excellence.  
  
Teaching methods include lecture, Q&A with faculty, case presentation and case discussion.

**Learning Objectives**

1 Discuss epidemiologic trends related to young age of onset colorectal cancer

2 Describe how specific intratumoral bacteria are associated with immune changes in the tumor microenvironment

3 Explore the emerging hereditary and environmental explanations in early onset colon cancers

4 Outline fertility preservation options available for colorectal cancer patients

5 Review consensus guidelines for anal cancer screening: who, how, when and why

6 Summarize guidelines suggesting TME-first approach in stage 1 rectal cancer

7 Explain the treatment and follow-up protocols for organ preservation

8 Discuss latest data on neoadjuvant chemotherapy for colon cancer

9 Identify scenarios in which up front surgery avoids over treatment with chemotherapy

10 Develop a framework for patient centered decision making in RT management decisions

11 Describe scenarios in which radiation can be avoided in locally advanced rectal cancer

12 Formulate anticoagulation plans based on current evidence, balancing risks, benefits, and patient preferences

13 Review endoscopic surveillance for colon cancer screening

14 Explain how MRI is the optimal modality for evaluation of extramural venous invasion (EMVI)

15 Assess the risk, diagnosis, and management of hepatotoxicity of chemotherapy and immunotherapy for CRC

**Accreditation**

Virginia Mason is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Logo, company name

Description automatically generated

**Credit Designation**

Virginia Mason designates this activity for a maximum of 5.25 *AMA PRA Category 1 Credit(s)*™.

**Faculty & Planners**

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| David M. Aboulafia, MD | Faculty | Nothing to disclose - 01/13/2025 |
| Sarah A. Ackermann, CCRC | Planning Committee Member | Nothing to disclose - 12/19/2024 |
| Bruce S. Lin, MD | Course Co-Director, Faculty | Grant or research support-Merck and Company, Inc.|Grant or research support-Tvardi|Grant or research support-Genentech, Inc.|Grant or research support-Exelixis|Grant or research support-Cardiff Oncology|Grant or research support-Zymeworks|Grant or research support-GlaxoSmithKline|Grant or research support-Relay Therapeutics|Grant or research support-Incyte - 12/20/2024 |
| Blaire E. Burman, MD | Faculty | Nothing to disclose - 03/10/2025 |
| Vlad Simianu, MD, MPH | Course Co-Director, Faculty | Consulting Fee-C-SATS (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-BD|Other: Travel and Education Support-Intuitive Surgical (Relationship has ended) - 05/18/2024 |
| Jenny Kaplan, MD | Faculty | Nothing to disclose - 01/24/2025 |
| Amber B. Post, MD, PhD | Course Co-Director, Faculty | Nothing to disclose - 03/20/2025 |
| Gautam Mankaney, MD | Faculty | Nothing to disclose - 09/19/2024 |
| Sirisha Jain, MD | Faculty | Nothing to disclose - 02/24/2025 |
| Emily Stevens, MD, PhD | Faculty | Nothing to disclose - 03/17/2025 |
| Ravi Moonka, MD, ASCRS | Faculty | Nothing to disclose - 03/17/2025 |
| Amanda Loh, MD | Faculty | Nothing to disclose - 03/17/2025 |
| Allyson Byrd, PhD | Faculty | Employment-Genentech, Inc. (Relationship has ended) - 03/14/2025 |
| Mohammad Hissourou III, MD | Faculty | Nothing to disclose - 03/17/2025 |
| Marianne E. Dubard-Gault, MD, MS | Faculty | Nothing to disclose - 03/14/2025 |
| Yi-Qian Nancy You, MD, MHSc, FACS | Faculty | Nothing to disclose - 02/13/2025 |
| Shelun Tsai, MD | Faculty | Nothing to disclose - 02/21/2025 |
| Rajeev Misra, DO, MS, FACS | Faculty | Honoraria-Intuitive Surgical - 03/11/2025 |

**Commercial Support**

This activity has been developed without commercial support.

**Virginia Mason**

**Evolving Care Across the Cancer Spectrum: The Latest Update in Colorectal Cancer**

March 21, 2025 7:30 AM

Volney Richmond Auditorium

**Description**

Virginia Mason Franciscan Health is a recognized leader across the spectrum of colorectal cancer care. This symposium aims to present important considerations in individualizing care across the cancer care continuum, with a focus on the increasing incidence of young-onset colorectal cancer. Topics include unique risk factors in the role of the microbiome and genetics in colorectal cancer development, fertility considerations and the latest in screening options.  
  
Our midday session will focus on important contemporary debates in colorectal cancer, and an application in a multidisciplinary tumor board context. Lastly, we will focus on managing treatment-related comorbidities and the nuances of continued surveillance.

The overall objective of the course is to demonstrate the benefits of contemporary, personalized care — nuanced decision making, latest trials, and individualized care as offered at a Center of Excellence.  
  
Teaching methods include lecture, Q&A with faculty, case presentation and case discussion.

**Learning Objectives**

1 Discuss epidemiologic trends related to young age of onset colorectal cancer

2 Describe how specific intratumoral bacteria are associated with immune changes in the tumor microenvironment

3 Explore the emerging hereditary and environmental explanations in early onset colon cancers

4 Outline fertility preservation options available for colorectal cancer patients

5 Review consensus guidelines for anal cancer screening: who, how, when and why

6 Summarize guidelines suggesting TME-first approach in stage 1 rectal cancer

7 Explain the treatment and follow-up protocols for organ preservation

8 Discuss latest data on neoadjuvant chemotherapy for colon cancer

9 Identify scenarios in which up front surgery avoids over treatment with chemotherapy

10 Develop a framework for patient centered decision making in RT management decisions

11 Describe scenarios in which radiation can be avoided in locally advanced rectal cancer

12 Formulate anticoagulation plans based on current evidence, balancing risks, benefits, and patient preferences

13 Review endoscopic surveillance for colon cancer screening

14 Explain how MRI is the optimal modality for evaluation of extramural venous invasion (EMVI)

15 Assess the risk, diagnosis, and management of hepatotoxicity of chemotherapy and immunotherapy for CRC

**Accreditation**

Virginia Mason is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Logo, company name

Description automatically generated

**Credit Designation**

Virginia Mason designates this activity for a maximum of 5.25 *AMA PRA Category 1 Credit(s)*™.

**Faculty & Planners**

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| David M. Aboulafia, MD | Faculty | Nothing to disclose - 01/13/2025 |
| Sarah A. Ackermann, CCRC | Planning Committee Member | Nothing to disclose - 12/19/2024 |
| Bruce S. Lin, MD | Course Co-Director, Faculty | Grant or research support-Merck and Company, Inc.|Grant or research support-Tvardi|Grant or research support-Genentech, Inc.|Grant or research support-Exelixis|Grant or research support-Cardiff Oncology|Grant or research support-Zymeworks|Grant or research support-GlaxoSmithKline|Grant or research support-Relay Therapeutics|Grant or research support-Incyte - 12/20/2024 |
| Blaire E. Burman, MD | Faculty | Nothing to disclose - 03/10/2025 |
| Vlad Simianu, MD, MPH | Course Co-Director, Faculty | Consulting Fee-C-SATS (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-BD|Other: Travel and Education Support-Intuitive Surgical (Relationship has ended) - 05/18/2024 |
| Jenny Kaplan, MD | Faculty | Nothing to disclose - 01/24/2025 |
| Amber B. Post, MD, PhD | Course Co-Director, Faculty | Nothing to disclose - 03/20/2025 |
| Gautam Mankaney, MD | Faculty | Nothing to disclose - 09/19/2024 |
| Sirisha Jain, MD | Faculty | Nothing to disclose - 02/24/2025 |
| Emily Stevens, MD, PhD | Faculty | Nothing to disclose - 03/17/2025 |
| Ravi Moonka, MD, ASCRS | Faculty | Nothing to disclose - 03/17/2025 |
| Amanda Loh, MD | Faculty | Nothing to disclose - 03/17/2025 |
| Allyson Byrd, PhD | Faculty | Employment-Genentech, Inc. (Relationship has ended) - 03/14/2025 |
| Mohammad Hissourou III, MD | Faculty | Nothing to disclose - 03/17/2025 |
| Marianne E. Dubard-Gault, MD, MS | Faculty | Nothing to disclose - 03/14/2025 |
| Yi-Qian Nancy You, MD, MHSc, FACS | Faculty | Nothing to disclose - 02/13/2025 |
| Shelun Tsai, MD | Faculty | Nothing to disclose - 02/21/2025 |
| Rajeev Misra, DO, MS, FACS | Faculty | Honoraria-Intuitive Surgical - 03/11/2025 |

**Commercial Support**

This activity has been developed without commercial support.

**Virginia Mason**

**Evolving Care Across the Cancer Spectrum: The Latest Update in Colorectal Cancer**

March 21, 2025 7:30 AM

Volney Richmond Auditorium

**Description**

Virginia Mason Franciscan Health is a recognized leader across the spectrum of colorectal cancer care. This symposium aims to present important considerations in individualizing care across the cancer care continuum, with a focus on the increasing incidence of young-onset colorectal cancer. Topics include unique risk factors in the role of the microbiome and genetics in colorectal cancer development, fertility considerations and the latest in screening options.  
  
Our midday session will focus on important contemporary debates in colorectal cancer, and an application in a multidisciplinary tumor board context. Lastly, we will focus on managing treatment-related comorbidities and the nuances of continued surveillance.

The overall objective of the course is to demonstrate the benefits of contemporary, personalized care — nuanced decision making, latest trials, and individualized care as offered at a Center of Excellence.  
  
Teaching methods include lecture, Q&A with faculty, case presentation and case discussion.

**Learning Objectives**

1 Discuss epidemiologic trends related to young age of onset colorectal cancer

2 Describe how specific intratumoral bacteria are associated with immune changes in the tumor microenvironment

3 Explore the emerging hereditary and environmental explanations in early onset colon cancers

4 Outline fertility preservation options available for colorectal cancer patients

5 Review consensus guidelines for anal cancer screening: who, how, when and why

6 Summarize guidelines suggesting TME-first approach in stage 1 rectal cancer

7 Explain the treatment and follow-up protocols for organ preservation

8 Discuss latest data on neoadjuvant chemotherapy for colon cancer

9 Identify scenarios in which up front surgery avoids over treatment with chemotherapy

10 Develop a framework for patient centered decision making in RT management decisions

11 Describe scenarios in which radiation can be avoided in locally advanced rectal cancer

12 Formulate anticoagulation plans based on current evidence, balancing risks, benefits, and patient preferences

13 Review endoscopic surveillance for colon cancer screening

14 Explain how MRI is the optimal modality for evaluation of extramural venous invasion (EMVI)

15 Assess the risk, diagnosis, and management of hepatotoxicity of chemotherapy and immunotherapy for CRC

**Accreditation**

Virginia Mason is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Logo, company name

Description automatically generated

**Credit Designation**

Virginia Mason designates this activity for a maximum of 5.25 *AMA PRA Category 1 Credit(s)*™.

**Faculty & Planners**

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| David M. Aboulafia, MD | Faculty | Nothing to disclose - 01/13/2025 |
| Sarah A. Ackermann, CCRC | Planning Committee Member | Nothing to disclose - 12/19/2024 |
| Bruce S. Lin, MD | Course Co-Director, Faculty | Grant or research support-Merck and Company, Inc.|Grant or research support-Tvardi|Grant or research support-Genentech, Inc.|Grant or research support-Exelixis|Grant or research support-Cardiff Oncology|Grant or research support-Zymeworks|Grant or research support-GlaxoSmithKline|Grant or research support-Relay Therapeutics|Grant or research support-Incyte - 12/20/2024 |
| Blaire E. Burman, MD | Faculty | Nothing to disclose - 03/10/2025 |
| Vlad Simianu, MD, MPH | Course Co-Director, Faculty | Consulting Fee-C-SATS (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-BD|Other: Travel and Education Support-Intuitive Surgical (Relationship has ended) - 05/18/2024 |
| Jenny Kaplan, MD | Faculty | Nothing to disclose - 01/24/2025 |
| Amber B. Post, MD, PhD | Course Co-Director, Faculty | Nothing to disclose - 03/20/2025 |
| Gautam Mankaney, MD | Faculty | Nothing to disclose - 09/19/2024 |
| Sirisha Jain, MD | Faculty | Nothing to disclose - 02/24/2025 |
| Emily Stevens, MD, PhD | Faculty | Nothing to disclose - 03/17/2025 |
| Ravi Moonka, MD, ASCRS | Faculty | Nothing to disclose - 03/17/2025 |
| Amanda Loh, MD | Faculty | Nothing to disclose - 03/17/2025 |
| Allyson Byrd, PhD | Faculty | Employment-Genentech, Inc. (Relationship has ended) - 03/14/2025 |
| Mohammad Hissourou III, MD | Faculty | Nothing to disclose - 03/17/2025 |
| Marianne E. Dubard-Gault, MD, MS | Faculty | Nothing to disclose - 03/14/2025 |
| Yi-Qian Nancy You, MD, MHSc, FACS | Faculty | Nothing to disclose - 02/13/2025 |
| Shelun Tsai, MD | Faculty | Nothing to disclose - 02/21/2025 |
| Rajeev Misra, DO, MS, FACS | Faculty | Honoraria-Intuitive Surgical - 03/11/2025 |

**Commercial Support**

This activity has been developed without commercial support.

**Virginia Mason**

**Evolving Care Across the Cancer Spectrum: The Latest Update in Colorectal Cancer**

March 21, 2025 7:30 AM

Volney Richmond Auditorium

**Description**

Virginia Mason Franciscan Health is a recognized leader across the spectrum of colorectal cancer care. This symposium aims to present important considerations in individualizing care across the cancer care continuum, with a focus on the increasing incidence of young-onset colorectal cancer. Topics include unique risk factors in the role of the microbiome and genetics in colorectal cancer development, fertility considerations and the latest in screening options.  
  
Our midday session will focus on important contemporary debates in colorectal cancer, and an application in a multidisciplinary tumor board context. Lastly, we will focus on managing treatment-related comorbidities and the nuances of continued surveillance.

The overall objective of the course is to demonstrate the benefits of contemporary, personalized care — nuanced decision making, latest trials, and individualized care as offered at a Center of Excellence.  
  
Teaching methods include lecture, Q&A with faculty, case presentation and case discussion.

**Learning Objectives**

1 Discuss epidemiologic trends related to young age of onset colorectal cancer

2 Describe how specific intratumoral bacteria are associated with immune changes in the tumor microenvironment

3 Explore the emerging hereditary and environmental explanations in early onset colon cancers

4 Outline fertility preservation options available for colorectal cancer patients

5 Review consensus guidelines for anal cancer screening: who, how, when and why

6 Summarize guidelines suggesting TME-first approach in stage 1 rectal cancer

7 Explain the treatment and follow-up protocols for organ preservation

8 Discuss latest data on neoadjuvant chemotherapy for colon cancer

9 Identify scenarios in which up front surgery avoids over treatment with chemotherapy

10 Develop a framework for patient centered decision making in RT management decisions

11 Describe scenarios in which radiation can be avoided in locally advanced rectal cancer

12 Formulate anticoagulation plans based on current evidence, balancing risks, benefits, and patient preferences

13 Review endoscopic surveillance for colon cancer screening

14 Explain how MRI is the optimal modality for evaluation of extramural venous invasion (EMVI)

15 Assess the risk, diagnosis, and management of hepatotoxicity of chemotherapy and immunotherapy for CRC

**Accreditation**

Virginia Mason is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Logo, company name

Description automatically generated

**Credit Designation**

Virginia Mason designates this activity for a maximum of 5.25 *AMA PRA Category 1 Credit(s)*™.

**Faculty & Planners**

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| David M. Aboulafia, MD | Faculty | Nothing to disclose - 01/13/2025 |
| Sarah A. Ackermann, CCRC | Planning Committee Member | Nothing to disclose - 12/19/2024 |
| Bruce S. Lin, MD | Course Co-Director, Faculty | Grant or research support-Merck and Company, Inc.|Grant or research support-Tvardi|Grant or research support-Genentech, Inc.|Grant or research support-Exelixis|Grant or research support-Cardiff Oncology|Grant or research support-Zymeworks|Grant or research support-GlaxoSmithKline|Grant or research support-Relay Therapeutics|Grant or research support-Incyte - 12/20/2024 |
| Blaire E. Burman, MD | Faculty | Nothing to disclose - 03/10/2025 |
| Vlad Simianu, MD, MPH | Course Co-Director, Faculty | Consulting Fee-C-SATS (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-BD|Other: Travel and Education Support-Intuitive Surgical (Relationship has ended) - 05/18/2024 |
| Jenny Kaplan, MD | Faculty | Nothing to disclose - 01/24/2025 |
| Amber B. Post, MD, PhD | Course Co-Director, Faculty | Nothing to disclose - 03/20/2025 |
| Gautam Mankaney, MD | Faculty | Nothing to disclose - 09/19/2024 |
| Sirisha Jain, MD | Faculty | Nothing to disclose - 02/24/2025 |
| Emily Stevens, MD, PhD | Faculty | Nothing to disclose - 03/17/2025 |
| Ravi Moonka, MD, ASCRS | Faculty | Nothing to disclose - 03/17/2025 |
| Amanda Loh, MD | Faculty | Nothing to disclose - 03/17/2025 |
| Allyson Byrd, PhD | Faculty | Employment-Genentech, Inc. (Relationship has ended) - 03/14/2025 |
| Mohammad Hissourou III, MD | Faculty | Nothing to disclose - 03/17/2025 |
| Marianne E. Dubard-Gault, MD, MS | Faculty | Nothing to disclose - 03/14/2025 |
| Yi-Qian Nancy You, MD, MHSc, FACS | Faculty | Nothing to disclose - 02/13/2025 |
| Shelun Tsai, MD | Faculty | Nothing to disclose - 02/21/2025 |
| Rajeev Misra, DO, MS, FACS | Faculty | Honoraria-Intuitive Surgical - 03/11/2025 |

**Commercial Support**

This activity has been developed without commercial support.

**Virginia Mason**

**Evolving Care Across the Cancer Spectrum: The Latest Update in Colorectal Cancer**

March 21, 2025 7:30 AM

Volney Richmond Auditorium

**Description**

Virginia Mason Franciscan Health is a recognized leader across the spectrum of colorectal cancer care. This symposium aims to present important considerations in individualizing care across the cancer care continuum, with a focus on the increasing incidence of young-onset colorectal cancer. Topics include unique risk factors in the role of the microbiome and genetics in colorectal cancer development, fertility considerations and the latest in screening options.  
  
Our midday session will focus on important contemporary debates in colorectal cancer, and an application in a multidisciplinary tumor board context. Lastly, we will focus on managing treatment-related comorbidities and the nuances of continued surveillance.

The overall objective of the course is to demonstrate the benefits of contemporary, personalized care — nuanced decision making, latest trials, and individualized care as offered at a Center of Excellence.  
  
Teaching methods include lecture, Q&A with faculty, case presentation and case discussion.

**Learning Objectives**

1 Discuss epidemiologic trends related to young age of onset colorectal cancer

2 Describe how specific intratumoral bacteria are associated with immune changes in the tumor microenvironment

3 Explore the emerging hereditary and environmental explanations in early onset colon cancers

4 Outline fertility preservation options available for colorectal cancer patients

5 Review consensus guidelines for anal cancer screening: who, how, when and why

6 Summarize guidelines suggesting TME-first approach in stage 1 rectal cancer

7 Explain the treatment and follow-up protocols for organ preservation

8 Discuss latest data on neoadjuvant chemotherapy for colon cancer

9 Identify scenarios in which up front surgery avoids over treatment with chemotherapy

10 Develop a framework for patient centered decision making in RT management decisions

11 Describe scenarios in which radiation can be avoided in locally advanced rectal cancer

12 Formulate anticoagulation plans based on current evidence, balancing risks, benefits, and patient preferences

13 Review endoscopic surveillance for colon cancer screening

14 Explain how MRI is the optimal modality for evaluation of extramural venous invasion (EMVI)

15 Assess the risk, diagnosis, and management of hepatotoxicity of chemotherapy and immunotherapy for CRC

**Accreditation**

Virginia Mason is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Logo, company name

Description automatically generated

**Credit Designation**

Virginia Mason designates this activity for a maximum of 5.25 *AMA PRA Category 1 Credit(s)*™.

**Faculty & Planners**

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| David M. Aboulafia, MD | Faculty | Nothing to disclose - 01/13/2025 |
| Sarah A. Ackermann, CCRC | Planning Committee Member | Nothing to disclose - 12/19/2024 |
| Bruce S. Lin, MD | Course Co-Director, Faculty | Grant or research support-Merck and Company, Inc.|Grant or research support-Tvardi|Grant or research support-Genentech, Inc.|Grant or research support-Exelixis|Grant or research support-Cardiff Oncology|Grant or research support-Zymeworks|Grant or research support-GlaxoSmithKline|Grant or research support-Relay Therapeutics|Grant or research support-Incyte - 12/20/2024 |
| Blaire E. Burman, MD | Faculty | Nothing to disclose - 03/10/2025 |
| Vlad Simianu, MD, MPH | Course Co-Director, Faculty | Consulting Fee-C-SATS (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-BD|Other: Travel and Education Support-Intuitive Surgical (Relationship has ended) - 05/18/2024 |
| Jenny Kaplan, MD | Faculty | Nothing to disclose - 01/24/2025 |
| Amber B. Post, MD, PhD | Course Co-Director, Faculty | Nothing to disclose - 03/20/2025 |
| Gautam Mankaney, MD | Faculty | Nothing to disclose - 09/19/2024 |
| Sirisha Jain, MD | Faculty | Nothing to disclose - 02/24/2025 |
| Emily Stevens, MD, PhD | Faculty | Nothing to disclose - 03/17/2025 |
| Ravi Moonka, MD, ASCRS | Faculty | Nothing to disclose - 03/17/2025 |
| Amanda Loh, MD | Faculty | Nothing to disclose - 03/17/2025 |
| Allyson Byrd, PhD | Faculty | Employment-Genentech, Inc. (Relationship has ended) - 03/14/2025 |
| Mohammad Hissourou III, MD | Faculty | Nothing to disclose - 03/17/2025 |
| Marianne E. Dubard-Gault, MD, MS | Faculty | Nothing to disclose - 03/14/2025 |
| Yi-Qian Nancy You, MD, MHSc, FACS | Faculty | Nothing to disclose - 02/13/2025 |
| Shelun Tsai, MD | Faculty | Nothing to disclose - 02/21/2025 |
| Rajeev Misra, DO, MS, FACS | Faculty | Honoraria-Intuitive Surgical - 03/11/2025 |

**Commercial Support**

This activity has been developed without commercial support.

**Virginia Mason**

**Evolving Care Across the Cancer Spectrum: The Latest Update in Colorectal Cancer**

March 21, 2025 7:30 AM

Volney Richmond Auditorium

**Description**

Virginia Mason Franciscan Health is a recognized leader across the spectrum of colorectal cancer care. This symposium aims to present important considerations in individualizing care across the cancer care continuum, with a focus on the increasing incidence of young-onset colorectal cancer. Topics include unique risk factors in the role of the microbiome and genetics in colorectal cancer development, fertility considerations and the latest in screening options.  
  
Our midday session will focus on important contemporary debates in colorectal cancer, and an application in a multidisciplinary tumor board context. Lastly, we will focus on managing treatment-related comorbidities and the nuances of continued surveillance.

The overall objective of the course is to demonstrate the benefits of contemporary, personalized care — nuanced decision making, latest trials, and individualized care as offered at a Center of Excellence.  
  
Teaching methods include lecture, Q&A with faculty, case presentation and case discussion.

**Learning Objectives**

1 Discuss epidemiologic trends related to young age of onset colorectal cancer

2 Describe how specific intratumoral bacteria are associated with immune changes in the tumor microenvironment

3 Explore the emerging hereditary and environmental explanations in early onset colon cancers

4 Outline fertility preservation options available for colorectal cancer patients

5 Review consensus guidelines for anal cancer screening: who, how, when and why

6 Summarize guidelines suggesting TME-first approach in stage 1 rectal cancer

7 Explain the treatment and follow-up protocols for organ preservation

8 Discuss latest data on neoadjuvant chemotherapy for colon cancer

9 Identify scenarios in which up front surgery avoids over treatment with chemotherapy

10 Develop a framework for patient centered decision making in RT management decisions

11 Describe scenarios in which radiation can be avoided in locally advanced rectal cancer

12 Formulate anticoagulation plans based on current evidence, balancing risks, benefits, and patient preferences

13 Review endoscopic surveillance for colon cancer screening

14 Explain how MRI is the optimal modality for evaluation of extramural venous invasion (EMVI)

15 Assess the risk, diagnosis, and management of hepatotoxicity of chemotherapy and immunotherapy for CRC

**Accreditation**

Virginia Mason is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Logo, company name

Description automatically generated

**Credit Designation**

Virginia Mason designates this activity for a maximum of 5.25 *AMA PRA Category 1 Credit(s)*™.

**Faculty & Planners**

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| David M. Aboulafia, MD | Faculty | Nothing to disclose - 01/13/2025 |
| Sarah A. Ackermann, CCRC | Planning Committee Member | Nothing to disclose - 12/19/2024 |
| Bruce S. Lin, MD | Course Co-Director, Faculty | Grant or research support-Merck and Company, Inc.|Grant or research support-Tvardi|Grant or research support-Genentech, Inc.|Grant or research support-Exelixis|Grant or research support-Cardiff Oncology|Grant or research support-Zymeworks|Grant or research support-GlaxoSmithKline|Grant or research support-Relay Therapeutics|Grant or research support-Incyte - 12/20/2024 |
| Blaire E. Burman, MD | Faculty | Nothing to disclose - 03/10/2025 |
| Vlad Simianu, MD, MPH | Course Co-Director, Faculty | Consulting Fee-C-SATS (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-BD|Other: Travel and Education Support-Intuitive Surgical (Relationship has ended) - 05/18/2024 |
| Jenny Kaplan, MD | Faculty | Nothing to disclose - 01/24/2025 |
| Amber B. Post, MD, PhD | Course Co-Director, Faculty | Nothing to disclose - 03/20/2025 |
| Gautam Mankaney, MD | Faculty | Nothing to disclose - 09/19/2024 |
| Sirisha Jain, MD | Faculty | Nothing to disclose - 02/24/2025 |
| Emily Stevens, MD, PhD | Faculty | Nothing to disclose - 03/17/2025 |
| Ravi Moonka, MD, ASCRS | Faculty | Nothing to disclose - 03/17/2025 |
| Amanda Loh, MD | Faculty | Nothing to disclose - 03/17/2025 |
| Allyson Byrd, PhD | Faculty | Employment-Genentech, Inc. (Relationship has ended) - 03/14/2025 |
| Mohammad Hissourou III, MD | Faculty | Nothing to disclose - 03/17/2025 |
| Marianne E. Dubard-Gault, MD, MS | Faculty | Nothing to disclose - 03/14/2025 |
| Yi-Qian Nancy You, MD, MHSc, FACS | Faculty | Nothing to disclose - 02/13/2025 |
| Shelun Tsai, MD | Faculty | Nothing to disclose - 02/21/2025 |
| Rajeev Misra, DO, MS, FACS | Faculty | Honoraria-Intuitive Surgical - 03/11/2025 |

**Commercial Support**

This activity has been developed without commercial support.

**Virginia Mason**

**Evolving Care Across the Cancer Spectrum: The Latest Update in Colorectal Cancer**

March 21, 2025 7:30 AM

Volney Richmond Auditorium

**Description**

Virginia Mason Franciscan Health is a recognized leader across the spectrum of colorectal cancer care. This symposium aims to present important considerations in individualizing care across the cancer care continuum, with a focus on the increasing incidence of young-onset colorectal cancer. Topics include unique risk factors in the role of the microbiome and genetics in colorectal cancer development, fertility considerations and the latest in screening options.  
  
Our midday session will focus on important contemporary debates in colorectal cancer, and an application in a multidisciplinary tumor board context. Lastly, we will focus on managing treatment-related comorbidities and the nuances of continued surveillance.

The overall objective of the course is to demonstrate the benefits of contemporary, personalized care — nuanced decision making, latest trials, and individualized care as offered at a Center of Excellence.  
  
Teaching methods include lecture, Q&A with faculty, case presentation and case discussion.

**Learning Objectives**

1 Discuss epidemiologic trends related to young age of onset colorectal cancer

2 Describe how specific intratumoral bacteria are associated with immune changes in the tumor microenvironment

3 Explore the emerging hereditary and environmental explanations in early onset colon cancers

4 Outline fertility preservation options available for colorectal cancer patients

5 Review consensus guidelines for anal cancer screening: who, how, when and why

6 Summarize guidelines suggesting TME-first approach in stage 1 rectal cancer

7 Explain the treatment and follow-up protocols for organ preservation

8 Discuss latest data on neoadjuvant chemotherapy for colon cancer

9 Identify scenarios in which up front surgery avoids over treatment with chemotherapy

10 Develop a framework for patient centered decision making in RT management decisions

11 Describe scenarios in which radiation can be avoided in locally advanced rectal cancer

12 Formulate anticoagulation plans based on current evidence, balancing risks, benefits, and patient preferences

13 Review endoscopic surveillance for colon cancer screening

14 Explain how MRI is the optimal modality for evaluation of extramural venous invasion (EMVI)

15 Assess the risk, diagnosis, and management of hepatotoxicity of chemotherapy and immunotherapy for CRC

**Accreditation**

Virginia Mason is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Logo, company name

Description automatically generated

**Credit Designation**

Virginia Mason designates this activity for a maximum of 5.25 *AMA PRA Category 1 Credit(s)*™.

**Faculty & Planners**

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| David M. Aboulafia, MD | Faculty | Nothing to disclose - 01/13/2025 |
| Sarah A. Ackermann, CCRC | Planning Committee Member | Nothing to disclose - 12/19/2024 |
| Bruce S. Lin, MD | Course Co-Director, Faculty | Grant or research support-Merck and Company, Inc.|Grant or research support-Tvardi|Grant or research support-Genentech, Inc.|Grant or research support-Exelixis|Grant or research support-Cardiff Oncology|Grant or research support-Zymeworks|Grant or research support-GlaxoSmithKline|Grant or research support-Relay Therapeutics|Grant or research support-Incyte - 12/20/2024 |
| Blaire E. Burman, MD | Faculty | Nothing to disclose - 03/10/2025 |
| Vlad Simianu, MD, MPH | Course Co-Director, Faculty | Consulting Fee-C-SATS (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-BD|Other: Travel and Education Support-Intuitive Surgical (Relationship has ended) - 05/18/2024 |
| Jenny Kaplan, MD | Faculty | Nothing to disclose - 01/24/2025 |
| Amber B. Post, MD, PhD | Course Co-Director, Faculty | Nothing to disclose - 03/20/2025 |
| Gautam Mankaney, MD | Faculty | Nothing to disclose - 09/19/2024 |
| Sirisha Jain, MD | Faculty | Nothing to disclose - 02/24/2025 |
| Emily Stevens, MD, PhD | Faculty | Nothing to disclose - 03/17/2025 |
| Ravi Moonka, MD, ASCRS | Faculty | Nothing to disclose - 03/17/2025 |
| Amanda Loh, MD | Faculty | Nothing to disclose - 03/17/2025 |
| Allyson Byrd, PhD | Faculty | Employment-Genentech, Inc. (Relationship has ended) - 03/14/2025 |
| Mohammad Hissourou III, MD | Faculty | Nothing to disclose - 03/17/2025 |
| Marianne E. Dubard-Gault, MD, MS | Faculty | Nothing to disclose - 03/14/2025 |
| Yi-Qian Nancy You, MD, MHSc, FACS | Faculty | Nothing to disclose - 02/13/2025 |
| Shelun Tsai, MD | Faculty | Nothing to disclose - 02/21/2025 |
| Rajeev Misra, DO, MS, FACS | Faculty | Honoraria-Intuitive Surgical - 03/11/2025 |

**Commercial Support**

This activity has been developed without commercial support.

**Virginia Mason**

**Evolving Care Across the Cancer Spectrum: The Latest Update in Colorectal Cancer**

March 21, 2025 7:30 AM

Volney Richmond Auditorium

**Description**

Virginia Mason Franciscan Health is a recognized leader across the spectrum of colorectal cancer care. This symposium aims to present important considerations in individualizing care across the cancer care continuum, with a focus on the increasing incidence of young-onset colorectal cancer. Topics include unique risk factors in the role of the microbiome and genetics in colorectal cancer development, fertility considerations and the latest in screening options.  
  
Our midday session will focus on important contemporary debates in colorectal cancer, and an application in a multidisciplinary tumor board context. Lastly, we will focus on managing treatment-related comorbidities and the nuances of continued surveillance.

The overall objective of the course is to demonstrate the benefits of contemporary, personalized care — nuanced decision making, latest trials, and individualized care as offered at a Center of Excellence.  
  
Teaching methods include lecture, Q&A with faculty, case presentation and case discussion.

**Learning Objectives**

1 Discuss epidemiologic trends related to young age of onset colorectal cancer

2 Describe how specific intratumoral bacteria are associated with immune changes in the tumor microenvironment

3 Explore the emerging hereditary and environmental explanations in early onset colon cancers

4 Outline fertility preservation options available for colorectal cancer patients

5 Review consensus guidelines for anal cancer screening: who, how, when and why

6 Summarize guidelines suggesting TME-first approach in stage 1 rectal cancer

7 Explain the treatment and follow-up protocols for organ preservation

8 Discuss latest data on neoadjuvant chemotherapy for colon cancer

9 Identify scenarios in which up front surgery avoids over treatment with chemotherapy

10 Develop a framework for patient centered decision making in RT management decisions

11 Describe scenarios in which radiation can be avoided in locally advanced rectal cancer

12 Formulate anticoagulation plans based on current evidence, balancing risks, benefits, and patient preferences

13 Review endoscopic surveillance for colon cancer screening

14 Explain how MRI is the optimal modality for evaluation of extramural venous invasion (EMVI)

15 Assess the risk, diagnosis, and management of hepatotoxicity of chemotherapy and immunotherapy for CRC

**Accreditation**

Virginia Mason is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Logo, company name

Description automatically generated

**Credit Designation**

Virginia Mason designates this activity for a maximum of 5.25 *AMA PRA Category 1 Credit(s)*™.

**Faculty & Planners**

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| David M. Aboulafia, MD | Faculty | Nothing to disclose - 01/13/2025 |
| Sarah A. Ackermann, CCRC | Planning Committee Member | Nothing to disclose - 12/19/2024 |
| Bruce S. Lin, MD | Course Co-Director, Faculty | Grant or research support-Merck and Company, Inc.|Grant or research support-Tvardi|Grant or research support-Genentech, Inc.|Grant or research support-Exelixis|Grant or research support-Cardiff Oncology|Grant or research support-Zymeworks|Grant or research support-GlaxoSmithKline|Grant or research support-Relay Therapeutics|Grant or research support-Incyte - 12/20/2024 |
| Blaire E. Burman, MD | Faculty | Nothing to disclose - 03/10/2025 |
| Vlad Simianu, MD, MPH | Course Co-Director, Faculty | Consulting Fee-C-SATS (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-BD|Other: Travel and Education Support-Intuitive Surgical (Relationship has ended) - 05/18/2024 |
| Jenny Kaplan, MD | Faculty | Nothing to disclose - 01/24/2025 |
| Amber B. Post, MD, PhD | Course Co-Director, Faculty | Nothing to disclose - 03/20/2025 |
| Gautam Mankaney, MD | Faculty | Nothing to disclose - 09/19/2024 |
| Sirisha Jain, MD | Faculty | Nothing to disclose - 02/24/2025 |
| Emily Stevens, MD, PhD | Faculty | Nothing to disclose - 03/17/2025 |
| Ravi Moonka, MD, ASCRS | Faculty | Nothing to disclose - 03/17/2025 |
| Amanda Loh, MD | Faculty | Nothing to disclose - 03/17/2025 |
| Allyson Byrd, PhD | Faculty | Employment-Genentech, Inc. (Relationship has ended) - 03/14/2025 |
| Mohammad Hissourou III, MD | Faculty | Nothing to disclose - 03/17/2025 |
| Marianne E. Dubard-Gault, MD, MS | Faculty | Nothing to disclose - 03/14/2025 |
| Yi-Qian Nancy You, MD, MHSc, FACS | Faculty | Nothing to disclose - 02/13/2025 |
| Shelun Tsai, MD | Faculty | Nothing to disclose - 02/21/2025 |
| Rajeev Misra, DO, MS, FACS | Faculty | Honoraria-Intuitive Surgical - 03/11/2025 |

**Commercial Support**

This activity has been developed without commercial support.

**Virginia Mason**

**Evolving Care Across the Cancer Spectrum: The Latest Update in Colorectal Cancer**

March 21, 2025 7:30 AM

Volney Richmond Auditorium

**Description**

Virginia Mason Franciscan Health is a recognized leader across the spectrum of colorectal cancer care. This symposium aims to present important considerations in individualizing care across the cancer care continuum, with a focus on the increasing incidence of young-onset colorectal cancer. Topics include unique risk factors in the role of the microbiome and genetics in colorectal cancer development, fertility considerations and the latest in screening options.  
  
Our midday session will focus on important contemporary debates in colorectal cancer, and an application in a multidisciplinary tumor board context. Lastly, we will focus on managing treatment-related comorbidities and the nuances of continued surveillance.

The overall objective of the course is to demonstrate the benefits of contemporary, personalized care — nuanced decision making, latest trials, and individualized care as offered at a Center of Excellence.  
  
Teaching methods include lecture, Q&A with faculty, case presentation and case discussion.

**Learning Objectives**

1 Discuss epidemiologic trends related to young age of onset colorectal cancer

2 Describe how specific intratumoral bacteria are associated with immune changes in the tumor microenvironment

3 Explore the emerging hereditary and environmental explanations in early onset colon cancers

4 Outline fertility preservation options available for colorectal cancer patients

5 Review consensus guidelines for anal cancer screening: who, how, when and why

6 Summarize guidelines suggesting TME-first approach in stage 1 rectal cancer

7 Explain the treatment and follow-up protocols for organ preservation

8 Discuss latest data on neoadjuvant chemotherapy for colon cancer

9 Identify scenarios in which up front surgery avoids over treatment with chemotherapy

10 Develop a framework for patient centered decision making in RT management decisions

11 Describe scenarios in which radiation can be avoided in locally advanced rectal cancer

12 Formulate anticoagulation plans based on current evidence, balancing risks, benefits, and patient preferences

13 Review endoscopic surveillance for colon cancer screening

14 Explain how MRI is the optimal modality for evaluation of extramural venous invasion (EMVI)

15 Assess the risk, diagnosis, and management of hepatotoxicity of chemotherapy and immunotherapy for CRC

**Accreditation**

Virginia Mason is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Logo, company name

Description automatically generated

**Credit Designation**

Virginia Mason designates this activity for a maximum of 5.25 *AMA PRA Category 1 Credit(s)*™.

**Faculty & Planners**

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| David M. Aboulafia, MD | Faculty | Nothing to disclose - 01/13/2025 |
| Sarah A. Ackermann, CCRC | Planning Committee Member | Nothing to disclose - 12/19/2024 |
| Bruce S. Lin, MD | Course Co-Director, Faculty | Grant or research support-Merck and Company, Inc.|Grant or research support-Tvardi|Grant or research support-Genentech, Inc.|Grant or research support-Exelixis|Grant or research support-Cardiff Oncology|Grant or research support-Zymeworks|Grant or research support-GlaxoSmithKline|Grant or research support-Relay Therapeutics|Grant or research support-Incyte - 12/20/2024 |
| Blaire E. Burman, MD | Faculty | Nothing to disclose - 03/10/2025 |
| Vlad Simianu, MD, MPH | Course Co-Director, Faculty | Consulting Fee-C-SATS (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-BD|Other: Travel and Education Support-Intuitive Surgical (Relationship has ended) - 05/18/2024 |
| Jenny Kaplan, MD | Faculty | Nothing to disclose - 01/24/2025 |
| Amber B. Post, MD, PhD | Course Co-Director, Faculty | Nothing to disclose - 03/20/2025 |
| Gautam Mankaney, MD | Faculty | Nothing to disclose - 09/19/2024 |
| Sirisha Jain, MD | Faculty | Nothing to disclose - 02/24/2025 |
| Emily Stevens, MD, PhD | Faculty | Nothing to disclose - 03/17/2025 |
| Ravi Moonka, MD, ASCRS | Faculty | Nothing to disclose - 03/17/2025 |
| Amanda Loh, MD | Faculty | Nothing to disclose - 03/17/2025 |
| Allyson Byrd, PhD | Faculty | Employment-Genentech, Inc. (Relationship has ended) - 03/14/2025 |
| Mohammad Hissourou III, MD | Faculty | Nothing to disclose - 03/17/2025 |
| Marianne E. Dubard-Gault, MD, MS | Faculty | Nothing to disclose - 03/14/2025 |
| Yi-Qian Nancy You, MD, MHSc, FACS | Faculty | Nothing to disclose - 02/13/2025 |
| Shelun Tsai, MD | Faculty | Nothing to disclose - 02/21/2025 |
| Rajeev Misra, DO, MS, FACS | Faculty | Honoraria-Intuitive Surgical - 03/11/2025 |

**Commercial Support**

This activity has been developed without commercial support.

**Virginia Mason**

**Evolving Care Across the Cancer Spectrum: The Latest Update in Colorectal Cancer**

March 21, 2025 7:30 AM

Volney Richmond Auditorium

**Description**

Virginia Mason Franciscan Health is a recognized leader across the spectrum of colorectal cancer care. This symposium aims to present important considerations in individualizing care across the cancer care continuum, with a focus on the increasing incidence of young-onset colorectal cancer. Topics include unique risk factors in the role of the microbiome and genetics in colorectal cancer development, fertility considerations and the latest in screening options.  
  
Our midday session will focus on important contemporary debates in colorectal cancer, and an application in a multidisciplinary tumor board context. Lastly, we will focus on managing treatment-related comorbidities and the nuances of continued surveillance.

The overall objective of the course is to demonstrate the benefits of contemporary, personalized care — nuanced decision making, latest trials, and individualized care as offered at a Center of Excellence.  
  
Teaching methods include lecture, Q&A with faculty, case presentation and case discussion.

**Learning Objectives**

1 Discuss epidemiologic trends related to young age of onset colorectal cancer

2 Describe how specific intratumoral bacteria are associated with immune changes in the tumor microenvironment

3 Explore the emerging hereditary and environmental explanations in early onset colon cancers

4 Outline fertility preservation options available for colorectal cancer patients

5 Review consensus guidelines for anal cancer screening: who, how, when and why

6 Summarize guidelines suggesting TME-first approach in stage 1 rectal cancer

7 Explain the treatment and follow-up protocols for organ preservation

8 Discuss latest data on neoadjuvant chemotherapy for colon cancer

9 Identify scenarios in which up front surgery avoids over treatment with chemotherapy

10 Develop a framework for patient centered decision making in RT management decisions

11 Describe scenarios in which radiation can be avoided in locally advanced rectal cancer

12 Formulate anticoagulation plans based on current evidence, balancing risks, benefits, and patient preferences

13 Review endoscopic surveillance for colon cancer screening

14 Explain how MRI is the optimal modality for evaluation of extramural venous invasion (EMVI)

15 Assess the risk, diagnosis, and management of hepatotoxicity of chemotherapy and immunotherapy for CRC

**Accreditation**

Virginia Mason is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Logo, company name

Description automatically generated

**Credit Designation**

Virginia Mason designates this activity for a maximum of 5.25 *AMA PRA Category 1 Credit(s)*™.

**Faculty & Planners**

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| David M. Aboulafia, MD | Faculty | Nothing to disclose - 01/13/2025 |
| Sarah A. Ackermann, CCRC | Planning Committee Member | Nothing to disclose - 12/19/2024 |
| Bruce S. Lin, MD | Course Co-Director, Faculty | Grant or research support-Merck and Company, Inc.|Grant or research support-Tvardi|Grant or research support-Genentech, Inc.|Grant or research support-Exelixis|Grant or research support-Cardiff Oncology|Grant or research support-Zymeworks|Grant or research support-GlaxoSmithKline|Grant or research support-Relay Therapeutics|Grant or research support-Incyte - 12/20/2024 |
| Blaire E. Burman, MD | Faculty | Nothing to disclose - 03/10/2025 |
| Vlad Simianu, MD, MPH | Course Co-Director, Faculty | Consulting Fee-C-SATS (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-BD|Other: Travel and Education Support-Intuitive Surgical (Relationship has ended) - 05/18/2024 |
| Jenny Kaplan, MD | Faculty | Nothing to disclose - 01/24/2025 |
| Amber B. Post, MD, PhD | Course Co-Director, Faculty | Nothing to disclose - 03/20/2025 |
| Gautam Mankaney, MD | Faculty | Nothing to disclose - 09/19/2024 |
| Sirisha Jain, MD | Faculty | Nothing to disclose - 02/24/2025 |
| Emily Stevens, MD, PhD | Faculty | Nothing to disclose - 03/17/2025 |
| Ravi Moonka, MD, ASCRS | Faculty | Nothing to disclose - 03/17/2025 |
| Amanda Loh, MD | Faculty | Nothing to disclose - 03/17/2025 |
| Allyson Byrd, PhD | Faculty | Employment-Genentech, Inc. (Relationship has ended) - 03/14/2025 |
| Mohammad Hissourou III, MD | Faculty | Nothing to disclose - 03/17/2025 |
| Marianne E. Dubard-Gault, MD, MS | Faculty | Nothing to disclose - 03/14/2025 |
| Yi-Qian Nancy You, MD, MHSc, FACS | Faculty | Nothing to disclose - 02/13/2025 |
| Shelun Tsai, MD | Faculty | Nothing to disclose - 02/21/2025 |
| Rajeev Misra, DO, MS, FACS | Faculty | Honoraria-Intuitive Surgical - 03/11/2025 |

**Commercial Support**

This activity has been developed without commercial support.

**Virginia Mason**

**Evolving Care Across the Cancer Spectrum: The Latest Update in Colorectal Cancer**

March 21, 2025 7:30 AM

Volney Richmond Auditorium

**Description**

Virginia Mason Franciscan Health is a recognized leader across the spectrum of colorectal cancer care. This symposium aims to present important considerations in individualizing care across the cancer care continuum, with a focus on the increasing incidence of young-onset colorectal cancer. Topics include unique risk factors in the role of the microbiome and genetics in colorectal cancer development, fertility considerations and the latest in screening options.  
  
Our midday session will focus on important contemporary debates in colorectal cancer, and an application in a multidisciplinary tumor board context. Lastly, we will focus on managing treatment-related comorbidities and the nuances of continued surveillance.

The overall objective of the course is to demonstrate the benefits of contemporary, personalized care — nuanced decision making, latest trials, and individualized care as offered at a Center of Excellence.  
  
Teaching methods include lecture, Q&A with faculty, case presentation and case discussion.

**Learning Objectives**

1 Discuss epidemiologic trends related to young age of onset colorectal cancer

2 Describe how specific intratumoral bacteria are associated with immune changes in the tumor microenvironment

3 Explore the emerging hereditary and environmental explanations in early onset colon cancers

4 Outline fertility preservation options available for colorectal cancer patients

5 Review consensus guidelines for anal cancer screening: who, how, when and why

6 Summarize guidelines suggesting TME-first approach in stage 1 rectal cancer

7 Explain the treatment and follow-up protocols for organ preservation

8 Discuss latest data on neoadjuvant chemotherapy for colon cancer

9 Identify scenarios in which up front surgery avoids over treatment with chemotherapy

10 Develop a framework for patient centered decision making in RT management decisions

11 Describe scenarios in which radiation can be avoided in locally advanced rectal cancer

12 Formulate anticoagulation plans based on current evidence, balancing risks, benefits, and patient preferences

13 Review endoscopic surveillance for colon cancer screening

14 Explain how MRI is the optimal modality for evaluation of extramural venous invasion (EMVI)

15 Assess the risk, diagnosis, and management of hepatotoxicity of chemotherapy and immunotherapy for CRC

**Accreditation**

Virginia Mason is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Logo, company name

Description automatically generated

**Credit Designation**

Virginia Mason designates this activity for a maximum of 5.25 *AMA PRA Category 1 Credit(s)*™.

**Faculty & Planners**

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| David M. Aboulafia, MD | Faculty | Nothing to disclose - 01/13/2025 |
| Sarah A. Ackermann, CCRC | Planning Committee Member | Nothing to disclose - 12/19/2024 |
| Bruce S. Lin, MD | Course Co-Director, Faculty | Grant or research support-Merck and Company, Inc.|Grant or research support-Tvardi|Grant or research support-Genentech, Inc.|Grant or research support-Exelixis|Grant or research support-Cardiff Oncology|Grant or research support-Zymeworks|Grant or research support-GlaxoSmithKline|Grant or research support-Relay Therapeutics|Grant or research support-Incyte - 12/20/2024 |
| Blaire E. Burman, MD | Faculty | Nothing to disclose - 03/10/2025 |
| Vlad Simianu, MD, MPH | Course Co-Director, Faculty | Consulting Fee-C-SATS (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-BD|Other: Travel and Education Support-Intuitive Surgical (Relationship has ended) - 05/18/2024 |
| Jenny Kaplan, MD | Faculty | Nothing to disclose - 01/24/2025 |
| Amber B. Post, MD, PhD | Course Co-Director, Faculty | Nothing to disclose - 03/20/2025 |
| Gautam Mankaney, MD | Faculty | Nothing to disclose - 09/19/2024 |
| Sirisha Jain, MD | Faculty | Nothing to disclose - 02/24/2025 |
| Emily Stevens, MD, PhD | Faculty | Nothing to disclose - 03/17/2025 |
| Ravi Moonka, MD, ASCRS | Faculty | Nothing to disclose - 03/17/2025 |
| Amanda Loh, MD | Faculty | Nothing to disclose - 03/17/2025 |
| Allyson Byrd, PhD | Faculty | Employment-Genentech, Inc. (Relationship has ended) - 03/14/2025 |
| Mohammad Hissourou III, MD | Faculty | Nothing to disclose - 03/17/2025 |
| Marianne E. Dubard-Gault, MD, MS | Faculty | Nothing to disclose - 03/14/2025 |
| Yi-Qian Nancy You, MD, MHSc, FACS | Faculty | Nothing to disclose - 02/13/2025 |
| Shelun Tsai, MD | Faculty | Nothing to disclose - 02/21/2025 |
| Rajeev Misra, DO, MS, FACS | Faculty | Honoraria-Intuitive Surgical - 03/11/2025 |

**Commercial Support**

This activity has been developed without commercial support.